Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

This phase 3 randomized controlled trial (REPRIEVE) evaluated the efficacy of pitavastatin (4 mg daily) versus placebo in 7769 HIV-positive adults at low-to-moderate cardiovascular risk. Over a median follow-up of 5.1 years, the pitavastatin group showed a 35% reduction in major adverse cardiovascular events including myocardial infarction, stroke, unstable angina, and cardiovascular death compared to placebo. The findings suggest statin therapy confers protection beyond LDL cholesterol reduction, potentially via anti-inflammatory effects. Adverse events like muscle symptoms and diabetes occurred slightly more in the treatment group but remained infrequent.

This phase 3 randomized controlled trial (REPRIEVE) evaluated the efficacy of pitavastatin (4 mg daily) versus placebo in 7769 HIV-positive adults at low-to-moderate cardiovascular risk. Over a median follow-up of 5.1 years, the pitavastatin group showed a 35% reduction in major adverse cardiovascular events including myocardial infarction, stroke, unstable angina, and cardiovascular death compared to placebo. The findings suggest statin therapy confers protection beyond LDL cholesterol reduction, potentially via anti-inflammatory effects. Adverse events like muscle symptoms and diabetes occurred slightly more in the treatment group but remained infrequent.